



James L. Rapholz's

ECONOMIC ADVICE

Fall 2007

Forget what you may think you know about stem cells!

Patented breakthrough:

- ▶ **Finally, there's a practical solution to the safety and ethical dilemma!** CellCyte's (OTCBB: CCYG) technology **can use the patient's own adult stem cells!**
- ▶ **Now, a practical "pill-in-a-bottle" application puts the miracle of regenerative medicine within immediate reach!** CellCyte's revolutionary technology is designed to deliver organ-specific adult stem cells to the target organ through the patient's blood and keeps them in the organ **to repair and regenerate damaged tissue.**

JVH629097A

Invest just \$5,000 now in the \$5 stock of CellCyte Genetics (OTCBB:CCYG) and you could have \$7 million...FIND OUT INSIDE!



**Theresa Deisher, Ph.D.,
Vice President Research
and Development**

The world's foremost expert on adult cardiac stem cells is determined to make regenerative medicine a safe, practical, affordable, everyday treatment!

This truly could be the most astonishing and important medical breakthrough in your lifetime!

At less than \$5 per share, CellCyte Genetics (OTCBB: CCYG) could be the chance of your lifetime to turn \$10,000 into \$4 million, maybe even \$15 million!

My name is James Raphael. I am editor and publisher of the well-read investment advisory, *ECONOMIC ADVICE*. For more than 20 years, I've been making investors rich by being early to unearth small, still-undiscovered stocks with blockbuster potential.

I'll tell you more about who I am and what I've done as you read on. But, since no stock recommendation is actionable if you don't have faith in the source, I'll quickly mention that some of my...

recent picks have racked up gains of 683%...772%...1,337%...1,610%...and even 6,500%!

I can substantiate all of those claims and as I said, you'll find more about me and my advisory *ECONOMIC ADVICE* as you read on.

But first, I want to go on record as saying that CellCyte Genetics (OTCBB: CCYG) is one of the most exciting companies, and represents one of the most compelling profit opportunities I've seen in a long, long time!

One of my reasons for having such faith in the company and its stock, is Doctor Theresa A. Deisher, Ph.D., widely recognized as a pre-eminent, world-authority on molecular and cellular physiology.

Doctor Deisher has a long and distinguished career in the biotech industry having held scientific and development responsibilities at such top biotech companies as Genetech, Repligen, ZymoGenetics, Immunex and Amgen. I mean it doesn't get any better than that!

Dr. Deisher was the first scientist to discover and characterize adult cardiac stem cells, for which she holds the U.S. patent.

Obviously, Doctor Deisher would not have given up her previous position to join CellCyte if she were not

confident in both the company and the opportunity to convert her discoveries into practical, potentially life-saving, safe, affordable treatments that could effect the lives of tens of millions.

As CellCyte's Vice President, Research and Development, Doctor Deisher heads an equally distinguished team of scientists and medical researchers, all of whom are working hard to fill the company pipeline with one extraordinary stem cell breakthrough after another.

I hope you enjoy this incredible story of how Dr. Deisher and her team at CellCyte Genetics (OTCBB: CCYG) could be making medical history...that you will decide to invest in this outstanding company...and that you will also want to accept a no-risk trial subscription to my monthly advisory *ECONOMIC ADVICE*.

James L. Raphael



“Repair your own heart!”

Regenerative medicine is on the verge of an enormous and historic leap forward.

The sky is the limit for the \$5 stock of CellCyte Genetics (OTCBB: CCYG), the unnoticed biotech company whose amazing technology could make stem cell therapy an ethically-acceptable, safe, practical, affordable reality for the millions who can benefit from it.

Dear Investor:

Imagine a cardiologist telling a patient who has just survived a serious heart attack that...“we don’t have a transplant available...we can’t medicate your heart condition...but you can grow new heart tissue to repair the damage!”

That’s what we’re talking about. And soon.

Traditional “cut-it” or “medicate-it” medicine is about to give way to “replace-it” medicine. And we’re not talking about test tube, or man-made replacements but rather...

grow-your-own repair tissues!

In the not-too-distant future, instead of using dangerous, not-very-effective, invasive procedures, or toxic, chemical medicines to treat heart attack patients, doctors should be able to inject stem cells, *from the patient’s own body*, into a vein

where the stem cells will target the heart to allow *growth and repair of damaged heart tissue!*

The technology is real. It’s here now. It’s heading into FDA testing. Because it’s based on safe, naturally occurring proteins, FDA fast tracking, if granted, could allow more rapid approval of this revolutionary treatment.

And stem cell treatment for the heart is just the first wave of therapeutic interventions in CellCyte’s pipeline. Right behind it are potential stem cell therapies for the liver... kidney...lungs and other organs. I believe it will absolutely revolutionize the practice of medicine!

I don’t care what you may have heard or read about stem cells before, medical science has finally come up with a safe, practical, affordable application that puts the promise of regenerative medicine within reach.



Here's why CellCyte (OTCBB: CCYG) is about to turn heads in the medical world:

CellCyte is developing its products to come in a single-use vial, priced so that patients who need it can afford it.

The Basics:

Stem cells, as you probably know, are cells in the human body that have the ability to continue dividing and that can change into specific cell types — bone, muscle, cartilage and other specialized cells — that make up your body.

Stem cell medicine, or regenerative medicine has been much heralded as the key to extending

and improving the quality of life for millions by actually repairing damaged organs, including the heart, lungs, liver, kidneys and even the spinal cord, which normally does not undergo regeneration.

Theoretically, stem cells might make it possible one day for a quadriplegic (remember Superman actor Christopher Reeves?) to walk again, or an amputee to grow a new limb, much as some species of lizards can grow a new tail after being half eaten by a predator.

There's been a lot of talk, a great deal of controversy, much excitement, and a great deal of promise, but until now, not much practical progress. Until now, a straight-forward application of stem cell technology has been stymied and has made therapeutic interventions impractical. The two main areas are:

- ▶ How to safely and affordably introduce stem cells into a targeted tissue (in the past, stem cells had to be injected into the damaged area of the heart in a very invasive procedure).
- ▶ How to direct stem cells to a specific organ and keep them there (using current methods only 1% to 5% of the stem cells stayed in the organ, not enough to adequately repair damage).

CellCyte Genetics now has the practical, real-world solutions:

First, CellCyte has a breakthrough patented technology that, for the first time, makes possible the direct, non-invasive delivery of adult stem cells (derived through the patient's own circulatory system), targeted and retained in the heart, liver, lung or kidney.

CellCyte has a patented way to use naturally occurring proteins to enhance delivery and not only does their technology target specific organs, in pre-clinical studies over 77% of the stem cells remained in place in the organ, compared to a mere 1% to 5% by current invasive methods. This is a stabilization that will allow the stem cells to perform their repair and regenerative miracles.

Second, CellCyte Genetics (OTCBB: CCYG) can use the patient's own *adult* stem cells, not the controversial embryonic form. The combination of CellCyte's patented biologic, CCGTH30 along with its bioreactor that is able to control cellular oxygen levels to emulate human body conditions, makes possible the dramatic growth of stem cells (extracted from the patient's own bone marrow) in culture for patient transplant applications. By itself, this is a



huge breakthrough that simply dissolves the ethical roadblocks.

Third, CellCyte's patented biologic acts like the software operating system for the introduced stem cells, so they remain in the desired location and accomplish the desired cellular function. And, the delivery "operating system" works with virtually any type of stem cell.

As Gary Reys, the chairman, president and CEO of the company explained to me:

"...you might look at us as the Microsoft operating system for stem cells. In the early era of computers, everybody rushed to build hardware and nobody focused on the operating systems. Microsoft went out and said... Hey, we don't care what kind of hardware (stem cells) you've got, we have a software system for your hardware to run on. With CellCyte's it's the same model: instead of developing a stem cell line or trying to differentiate kinds of stem cells (the HARDWARE), CellCyte has basically developed an operating (delivery) system for all stem cells."

CellCyte's patented technology heralds a new branch of medicine that will be worth \$billions upon billions!

The small biotech company behind this stem cell breakthrough is CellCyte Genetics Inc. (OTCBB: CCYG).

The company was launched 3 years ago by two veteran giants of the biotech world; Gary Reys, a biotech pharmaceutical executive with 30 years of top-level experience and Dr. Ronald Berninger, a Ph.D. scientist who is an expert on stem cell medicine. .

CellCyte stock (OTCBB: CCYG) has been trading around \$5, but...

I'm looking for \$5 to explode to \$25 in the next 12 to 18 months and, and long term, if the company isn't taken over at \$125, to \$200 a share or more...

This stock has the potential to turn a \$10,000 investment into \$4 million the way Microsoft did...

Maybe even grow \$10,000 into \$15 million in just 10 years the same way early investors got rich on Intel.

Read on and you will see that I'm not exaggerating nor am I suffering from "irrational exuberance."

CellCyte is in the process of transitioning regenerative medicine from the theoretical to a practical, life-saving, life-altering \$20 billion-a-year business that could have as significant an impact on world health, longevity and the quality of life as did the discovery of penicillin, the advent of antibiotics, the Salk vaccine, or the mapping of the human genome.

In the foreseeable future, (as soon as 3 to 5 years) an incredible, blockbuster and patented technology, that plans to seek FDA Fast Track designation, could make it simple, affordable and routine to deliver stem cells (derived from a patient's own blood and bone marrow) to afflicted organs — heart, liver, kidney and lung to begin with — and to retain them in place, so that the stem cells can repair and replace damaged tissue and muscle.

► Soon a heart attack victim could quite literally be able to grow new heart tissue and regain significant heart function with the use of their own stem cells. For the more than one million Americans who suffer a debilitating, heart attack each year, that's good news since

continued on page 6



second attacks are usually fatal. It could mean the difference between merely existing and a fuller, more active and productive life. For you, as an investor, it means huge profits!

- ▶ Expensive, life-disrupting kidney dialysis could be a thing of the past when this amazing technology uses the patient's own stem cells to repair damaged and failing kidneys.
- ▶ Soon, CellCyte's patented technology could make it possible to deliver stem cells to the heart, lungs and liver where they will repair and replace damaged tissue.
- ▶ One day, it's hoped that their technology may work against cancer and may even enable people crippled by severed nerves to walk again.

This could be the most astonishing investment opportunity since the microchip!

I want you to buy CellCyte Genetics (OTCBB: CCYG) now while it's still under \$5. Let me say again, this is a stock with the long-term potential of a Microsoft or an Intel.

When did you, or the Wall Street pundits, first recognize the true significance of the microchip?

Back in the 70s, many investors scoffed at the notion that one day we'd be toting wireless personal computers that would connect us instantly with each other and with a virtually infinite wealth of information and services.

By the late 90s, insightful investors who bought early Microsoft had seen a \$10,000 investment grow to over \$4 million!

Investors who recognized the impact of Intel's technology turned \$10,000 into \$15 million in less than 10 years!

I believe CellCyte has that kind of long term profit potential!

I admit, that until just recently, I was skeptical about stem cell medicine. But now that I understand what CellCyte Genetics is up to, now that I know who the biotech and medical giants are who are spearheading development, I'm telling you that CellCyte Genetics (OTCBB: CCYG) could make stem cell therapy a reality.

CellCyte could be the center of a \$20 billion market by 2010!

According to a report I read in the June 2007 issue of Medical News, the worldwide market for stem cell, cytokine and growth factor therapies was estimated at \$12.7 billion in 2005 and, rising at an average annual growth rate of 10.3 percent.

The global market is expected to reach \$20.7 billion in 2010. Nearly 98 percent of the market is consumed by blood and immune system treatments, according to BBC Research, a leading information resource. And blood systems are precisely where CellCyte is positioning itself.

CellCyte Genetics is leading the stem cell revolution that will hope-

fully make possible exciting new options for the treatment of heart, lung, kidney and liver disease. CellCyte is way in front with a practical, realistic way to make the promises of stem cell research a reality.

Stem cells will make possible a variety of new treatments.

More than one million people in the U.S. suffer a heart attack each year. The annual cost of heart disease, in the U.S. alone, is \$151 billion. Imagine how rich you'd be if CellCyte captures even a small part of that market.

Each year in America liver disease effects millions and adds significantly to medical costs. A treatment that could regenerate liver tissue could be worth tens of millions in revenue to CellCyte each year.

In the U.S. alone, the regeneration of kidney and lung tissue could easily generate hundreds of millions more for CellCyte!

And those numbers are based solely on first-stage technology. CellCyte has an impressive pipeline of patent-pending technologies that one day may be used in the fight against cancer of the prostate, lung, colon, pancreas and thyroid.

When could it all happen?

A good question indeed.

Short answer: Don't put off buying the stock! Remember what happened to investors who took a

wait and see attitude toward Microsoft and Intel. CellCyte's stock is positioned for explosive appreciation.

CellCyte is on target to file an IND (Initial New Drug) application with the FDA in early 2008 and begin actual Phase I clinical trials shortly thereafter.

Because of the unmet medical needs of heart attack patients and because of the safety profile of their naturally-occurring modified protein product, CellCyte hopes to win FDA fast-track approval that could put this potentially life-saving product on the market far faster than ordinary drug therapies.

Now, here's what, for me, was the clincher in all this...the answers to the all-important question of who are the people behind the technology and the equally important business end of things:

An Absolutely World-Class Team!

Breakthrough technology isn't worth much without the management



Gary A Reys
CEO, President and Chairman

and entrepreneurial experience to guide it successfully and profitably to market.

CellCyte Genetics has both a world-renowned cardiovascular scientist and biotech researcher and a seasoned, successful CEO with more than 30 years experience leading divisions of international Fortune 100 and 500 publicly traded companies, notably emerging growth firms in the pharmaceutical, biotechnology and medical device sectors.

Gary A. Reys held executive positions with Pfizer and with Rhone Poulenc Rorer (now Aventis), North America.

As a member of the founding management team of Schein Pharmaceutical, Mr. Reys was a pioneer in the genetic pharmaceutical industry, helping take the company public and its acquisition by Bayer AG. He was also CEO and President of Genespan, a cell expansion and DNA biotechnology company, which CellCyte acquired.

Under the leadership of Mr. Reys, CellCyte Genetics has focused since it was formed in 2003 on the acquisition of technologies that were already patented or had patents pending covering breakthrough technology discoveries that were far down the research and development pathway. This approach mitigates many of the risks associated with start-up and early stage companies and allows CellCyte to take these products to market at a much more rapid pace.

continued on page 8



CellCyte Genetics is emerging as the biotechnology leader in the discovery and development of breakthrough stem cell therapeutic products that make it possible to safely deliver stem cells through the patient's own circulatory/vascular system directly into a specific diseased, damaged or dying organ.





For the patient who has suffered a major heart attack, CellCyte's breakthrough stem cell technology could mean the difference between merely surviving and returning to an active life.


As Gary Reys explained to me...

"CellCyte has an extensive and broad intellectual property framework and product pipeline in place consisting of U.S. patents issued, and both U.S. and foreign patents pending for numerous therapeutic discoveries relating to the world's first stem cell organ delivery and organ repair compounds.

"CellCyte has finalized licensing of our three lead product candidates and now owns worldwide Patent Sole Ownership — Exclusive License to these technologies as well, which are viewed as the leader in advancements in stem cell delivery and organ targeting of stem cells to the heart, lung, liver and kidney for organ regeneration and repair.

"CellCyte's business platform is now well understood by the investment communities as we are the first company in the stem cell sector to offer a true blockbuster product platform and true revenue model. It is a very sound platform, one-of-a-kind in the world. We are the leader in non-invasive cell (stem-cell) delivery, with a true biologic product supplied in a vial; 'the pill in the bottle.'"

Looking back over the past year, Reys told me that CellCyte has accomplished its goals, having completed licensing negotiations and the acquisition of the assets of another biotechnology company, greatly expanded patent intellectual



**Theresa Deisher, Ph.D. ,
Vice President Research
and Development**

property platforms, hired key individuals, identified and executed a lease on a corporate and research facility, and funded CellCyte externally as a public company.

He also noted the company's fiscally responsible burn rate, its strong financials and its debt-free position, so all their money is for product development and moving the company forward to revenues. Pretty convincing! But the scientific foundation is equally impressive:

Doctor Deisher is an internationally renowned cardiovascular scientist with extensive expertise in the biotechnology industry. Her accomplishments include being the first scientist to discover and characterize adult cardiac stem cells, for which she holds the patent.

Throughout her career, Dr. Deisher has held positions of scientific and development responsibility with cutting-edge biotechnology companies including Genetech,

Repligen, ZymoGenetics, Immunex Corporation and Amgen.

CellCyte has also assembled a prestigious roster of experts to join its Scientific & Medical Advisory Board.

Mr. Reys, Doctor Deisher and their experienced management team believe the potential for CellCyte's breakthrough technologies are tremendous and could be the major medical step forward in saving millions of lives in this century.

I agree. And that's why I'm urging you to run, not walk, to your PC or phone and buy shares of CellCyte Genetics (OTCBB: CCYG) now before Wall Street wakes up to it.

Who am I and why should you act on my recommendation?

As I said before, my name is James Raphael and I am editor of *ECONOMIC ADVICE*, an investment advisory that's been making subscribers rich for over 20 years.

My passion is finding overlooked stocks in a hot sector, that because of some oddity, or peculiar situation (as with **CellCyte (OTCBB:CCYG)** are poised for lift off.

Nothing gives me more of a kick than uncovering a story like the one you're about to read (when Wall Street still doesn't have a clue) getting out the word, and then watching in complete satisfaction as everything I predicted comes true.

Over the past few years I've been mining the natural resources sector, because (as Al Capone said)

that's where the money has been. I have a hard-to-beat track record of recommendations that have racked up profits like these:

- ▶ **772% profit on Consol energy**
- ▶ **349% profit on Kinross Gold**
- ▶ **237% profit on Megellan Petroleum**
- ▶ **610% profit on GeoGlobal Resources**
- ▶ **737% profit on Lumina Copper**
- ▶ **502% profit on Great Basin Gold**
- ▶ **683% profit on Tenton energy**
- ▶ **1,337% profit on Yamana Resources**
- ▶ **1,610% profit on Zimbabwe Platinum**
- ▶ **6,500% profit on Crown Resources**

These are the kind of fortune-building opportunities I try and bring my subscribers in every issue of *Economic Advice* and I am confident that CellCyte is going to outperform even the best of these huge winners.

You undoubtedly noticed that the ten big winners above, happen to be energy and natural resource stocks. That's because that's the sector that's been red hot.

continued on page 10



Stem cells are undifferentiated precursor cells that can perpetuate themselves as stem cells (called self renewal), or that can differentiate into many different specialized cell types, such as heart cells. Stem cells are at the center of the new field of regenerative medicine.





But, now I'm on to something a bit different, a biotech that I believe can match or even eclipse some of those huge natural resource gains.

CellCyte is still relatively small, but I believe its team of world-renowned, absolutely-top experts in the field of regenerative medicine can make it a major force in a \$-billions-a-year sector.

I believe CellCyte is going to turn a lot of heads in the medical world!

I am convinced that **CellCyte (OTCBB:CCYG)** represents the beginning of a new era in biotechnology that will save millions of

lives, contribute to the quality of life and make many savvy investors very, very rich!

More big winners guaranteed!

I hope you will invest now in **CellCyte (OTCBB:CCYG)**, and I also hope you'll be tempted by it to accept a no-risk trial subscription to my advisory. You'll find details on the next page.

James L. Rapholz

IMPORTANT DISCLAIMER: This paid advertising issue of Economic Advice, its publisher, and its editor do not purport to provide an analysis of any company's financial position and is not in any way to be construed as an offer to buy or sell or a solicitation to an offer to buy or sell any security. The publisher and editor are not, and do not purport to be, registered investment advisors. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Investing in securities is speculative and carries a high degree of risk. Stockgroup AG (hereafter "Stockgroup") funded the printing and distribution of this publication (also called the "Report"). James Rapholz (the "Editor") and James Rapholtz doing business as James Rapholtz, Economic Advice (the "Publisher") provided an independent editorial review of all copy, and provided editorial supervision regarding the publishing of this Report. James Rapholz and James Rapholtz, Economic Advice were paid an Editorial Consulting Fee by Stockgroup to conduct a final independent editorial review and to supervise and oversee the independent investigative writing of this Report. Neither the Editor nor the Publisher as distributor and marketing agent for the publication, holds or has been promised, either directly or indirectly, any securities interest in CellCyte in consideration for any work or any contribution on their respective parts towards the creation, publication and distribution of this Report. The factual information contained in this Report specifically pertaining to CellCyte business, operations or financial records (the "CellCyte Facts") has been reviewed and verified for accuracy by CellCyte. The CellCyte Facts are believed to be reliable by the Editor and Publisher; however, they make no warranties as to the accuracy of any of that specific content and accept no liability for how readers may choose to utilize the CellCyte Facts. The factual information contained in this Report, other than the CellCyte Facts, is being republished from already publicly disseminated information and sources published by third parties, forming part of the public domain and although such public domain information relied upon by the Editor and Publisher in this Report is assumed to be accurate and reliable, the Editor and Publisher have not done any further follow-up investigation beyond the primary source from which such public domain information was obtained and therefore the Editor and Publisher accept no responsibility for the accuracy of such information nor do they accept liability for how readers may choose to utilize it. The views and opinions contained in this Report are the product of editorial independence ("Editorial Opinion") based on the investigation and due diligence of the Editor and his staff. The recommendation of the Editor, and the Publisher is that THE READER, as a matter of common sense, prudence and sound investment practice, should independently verify all statements made in this Report in the same manner as they should with any other advertisement, promotion, business report or similar publication before contemplating any form of investment. Disclosure of financial interests involving the creation of this publication includes: (1) The Editor and editorial staff were paid a total of US\$ 12,500 in editorial fees to undertake an independent investigation and due diligence in regard to the editorial review of all aspects of this report; (2) the Publisher also was remunerated part of the editorial fees to ensure the final copy was in a form consistent with general industry standards for a publication of this nature; (3) the total amount paid for the production and distribution of this publication is \$929,000 which has been paid for by Stockgroup AG; (4) James Rapholtz and James Rapholtz, Economic Advice are also expected to gain additional subscription revenues from anticipated growth in their subscriber base as a result of participating in this publication.

This publication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company and/or industry. In accordance with the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, the publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company's actual results of operations. The information contained herein includes forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Reference is made in particular to the description of CellCyte's plans and objectives for future operations, assumptions underlying such plans and objectives and other forward-looking statements included in the information provided. Such statements, which contain terms such as "expect," "believe," "anticipate," "suggest," "plan," "indicate" and similar terms of uncertainty, are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Factors which could cause such results to differ materially from those described in the forward-looking statements include the size and growth of the market for the Company's products, regulatory approvals, the ability to fund its capital requirements in the near term and the long term, developments by competitors which could impact the company's operations; fluctuations in prices; armed conflicts and or terrorist activities which could effect the economy and or the public equity markets, effects of naked short selling and other market pressures; and similar related issues.

GET 3 FREE BONUS REPORTS

on the biggest money-making opportunities today

Subscribe today and save up to \$146!

Yes! I want to cash in on the stem cell revolution with stocks such as CellCyte Genetics (OTCBB: CCYG) and others featured each month in the pages of James L. Rapholz's *Economic Advice*. Sign me up today for the following Special Offer...

STEP #1 Choose the offer you want:

(Please check one of the following four options.):

Hard Copy Subscriptions (sent by mail).

- 12 Monthly Issues for just \$149. Includes email updates, unlimited website access, plus one **FREE** Bonus Report.
- 24 Monthly Issues for just \$199. **Save \$100 and get all 3 Bonus Reports**, plus everything that comes with a 12-issue subscription.

Save an Extra \$50 on Email Subscriptions (sent by Email).

- 12 Monthly Email Issues for just \$99. Includes all additional materials that come with a 12-issue hard copy subscription.

Best Deal of All!

- 24 Monthly Email Issues for just \$149. Including all additional materials that come with a 24-issue hard copy subscription.

Send all email issues to this email address _____

Send all other materials to:

Name _____

Address _____

City _____ State _____ Zip _____

Phone Number _____
(for verification only)

STEP #2 Payment Options:

- Enclosed is my check/money order payable to James L. Rapholz for:
\$ _____ (US)

Bill my: VISA MasterCard Amex Discover

Card # _____

3-Digit security code _____ Expiration Date _____

Signature _____

Daytime Phone _____ Email _____
(Required for credit card orders)

Name on Card _____

Address _____

City _____ State _____ Zip _____
(Required for delivery of your newsletters)

STEP #3 Send in your request today!

For fastest service, phone Toll-Free 1-866-903-7100

(24 hours a day, 7 days a week)

Or visit www.economicadviceinc.com

Otherwise, mail your request today to: James L. Rapholz's *Economic Advice*
3907 N. Federal Hwy #185, Pompano Beach, FL 33064

Your 100% Risk-FREE Guarantee

Remember, if you are less than fully satisfied, just let us know within 30 days. I will cancel your subscription and sent you a full refund. And even after that, you can cancel anytime and get a refund of the balance of your subscription. No questions asked.

James L. Rapholz

An historic breakthrough in stem cell technology promises a new era of regenerative medicine.

CellCyte Genetics (OTCBB: CCYG) owns the patent that's leading the revolution!

Buy CellCyte now (OTCBB: CCYG) while it's still around \$5 and look for a 400% gain in the next 12 to 18 months!

